Lilly Revisits Priorities: GMPs Awarded Same Status As R&D, Marketing
Executive Summary
Lilly is rearranging its operating priorities to put manufacturing processes on the same level as R&D and sales and marketing, CEO Sidney Taurel told investors
You may also be interested in...
FDA Drug Development Efforts Are “Revolutionary,” Lilly’s Taurel Says
FDA Commissioner McClellan's plan to accelerate drug development is "the single most encouraging story now emerging in our field," Lilly CEO Sidney Taurel declared during a Hudson Institute-sponsored luncheon in Washington, D.C. Nov. 4
FDA Drug Development Efforts Are “Revolutionary,” Lilly’s Taurel Says
FDA Commissioner McClellan's plan to accelerate drug development is "the single most encouraging story now emerging in our field," Lilly CEO Sidney Taurel declared during a Hudson Institute-sponsored luncheon in Washington, D.C. Nov. 4
Lilly GMPs Clear One Milestone; Cymbalta Launch Now Planned For Summer
Lilly plans to launch Cymbalta in summer 2004, pending a pre-approval inspection and the build-up of sufficient product inventory